Hypolipidemic effect of brown seaweed (Sargassum crassifolium) extract in vivo (Study of histopathology, mRNA expression, and immunohistochemistry (IHC) with VCAM-1, ICAM-1, and MCP-1 parameters)

Sarah Zaidan,Syamsudin Abdillah,Nur Arfian,Wawaimuli Arozal

2024-02-12

Abstract:The purpose of this study was to obtain natural drugs from brown seaweed (Sargassum crassifolium) as antiatherosclerosis candidates through the study of hypolipidemic mechanisms of action. Modeling of dyslipidemia rats was carried out by feeding high-fat (HFF) and doses of crude fucoidan 100. 200. 400mg / KgBB. in both treatments measured blood lipid profile levels taken from the orbital sinuses. HE's histopathology. mRNA expression. immunohistochemistry (IHC) with parameters VCAM-1. ICAM-1. and MCP-1 were performed on adipose tissue. as well as liver. Total cholesterol values 51.07-225.2. triglycerides 30.43-115.73. HDL 13.1-24.86 mg/dl and LDL 20.22-189.68 mg/dl. In the treatment of crude fucoidan obtained the result of p value < {\alpha} (0.05. Histopathological features of adipose tissue after administration of HFF for 60 days resulted in an increase in adipose cell size. and the liver experienced structural damage and inflammation. but after 21 days of treatment the morphological picture of adipose tissue was similar to normal morphology and the liver also decreased in severity and inflammation. The results of histochemical staining after treatment showed a positive staining part on MCP-1. The result of p value < {\alpha} (0.05) of mRNA expression for administration of 3 treatment doses. A dyslipidemic mouse model with HFF administration for 60 days succeeded in becoming a dyslipidemic rat. and crude fucoidan had hypolipidemic activity. Doses of 100. 200. and 400 mg/KgBB crude fucoidan showed improvement in adipose and liver morphological features of severity and inflammation of dyslipidemic rats and decreased mRNA expression.

Biomolecules,Tissues and Organs

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the lipid - lowering effect of the extract of brown algae (Sargassum crassifolium) on hyperlipidemia in vivo and its potential as a candidate drug for anti - atherosclerosis. Specifically, the study addresses the problem through the following aspects:

1. **Establishment of hyperlipidemia animal model**: By feeding rats a high - fat diet (HFF), the pathological state of human hyperlipidemia is simulated.
2. **Evaluation of the lipid - lowering effect of brown algae extract**: Hyperlipidemia rats are treated with different doses of crude fucoidan, and the lipid profile levels in their blood, including total cholesterol, triglycerides, HDL and LDL, are measured.
3. **Histopathological analysis**: The histopathological changes of adipose tissue and liver are observed by HE staining to evaluate the effect of brown algae extract on these tissues.
4. **Gene expression analysis**: The mRNA expression of inflammation - related genes such as VCAM - 1, ICAM - 1 and MCP - 1 in the liver is detected by real - time quantitative PCR (RT - PCR) technology.
5. **Immunohistochemical analysis**: The expression of MCP - 1 protein in the liver is detected by immunohistochemistry (IHC) technology.

### Research background and the importance of the problem

Hyperlipidemia is one of the main risk factors for coronary heart disease. In Indonesia, about 36 million people (about 18% of the population) are affected by this disease. Hyperlipidemia not only leads to vascular endothelial dysfunction, but also increases the risk of atherosclerosis, which in turn leads to cardiovascular diseases. Current treatment methods mainly focus on relieving symptoms or affecting hemodynamic responses, but often cannot fundamentally solve the problem. Therefore, it is of great significance to search for anti - hyperlipidemia drugs from natural sources.

### Main research content

1. **Experimental design**:
- 36 male Wistar rats are selected and divided into 6 groups for the experiment.
- The experimental groups are treated with different doses of crude fucoidan (100 mg/kg, 200 mg/kg and 400 mg/kg), and the control groups are treated with distilled water or simvastatin.
- The treatment period is 21 days, during which the blood lipid levels are regularly measured.

2. **Result analysis**:
- **Blood lipid levels**: The results show that after 21 days of treatment, crude fucoidan significantly reduces the levels of total cholesterol, triglycerides and LDL, and at the same time increases the HDL level.
- **Histopathology**: HE staining shows that after treatment with crude fucoidan, the pathological changes in adipose tissue and liver are significantly alleviated and the degree of inflammation is reduced.
- **Gene expression**: RT - PCR results show that crude fucoidan significantly reduces the mRNA expression of VCAM - 1, ICAM - 1 and MCP - 1.
- **Immunohistochemistry**: IHC results show that crude fucoidan reduces the expression of MCP - 1 protein in the liver.

### Conclusion

The study shows that the extract of brown algae (Sargassum crassifolium) has a significant lipid - lowering effect, can improve the lipid profile levels of hyperlipidemia rats, reduce the pathological damage of adipose tissue and liver, and reduce the gene expression related to inflammation. This indicates that the brown algae extract may be a potential anti - atherosclerotic drug.

### Formula display

The formulas involved in the discussion are shown in Markdown format as follows:

- Percentage change of total cholesterol level:
\[
\text{Percentage change}=\left(\frac{\text{Post - treatment level}-\text{Pre - treatment level}}{\text{Pre - treatment level}}\right)\times100\%
\]

- Significance test of mRNA expression difference (One - Way ANOVA):
\[
F = \frac{\text{Between - group mean square}}{\text{Within - group mean square}}
\]
where the \(F\) value is used to determine whether there are significant differences between groups.

I hope this information can help you better understand the research purpose and main content of this paper.